Inhaled corticosteroid (ICS) therapy can be associated not only with rare systemic adverse events (ADEs) but also, more commonly, with oropharyngeal ADEs. The authors investigate the economic burden of ICS treatment.
You are here
P&T® Journal contents for October 2005
Impact of Inhaled Corticosteroid–Induced Oropharyngeal Side Effects on Treatment Patterns and Costs in Asthmatic Patients: Results from a Delphi Panel
Clinical and Economic Outcomes of Prolonged Postoperative Ileus in Patients Undergoing Hysterectomy and Hemicolectomy
The authors examine the clinical and economic implications of PPOI within a patient population undergoing abdominal surgeries at a major urban academic medical center.
Dr. Goldenberg discusses new indications for levofloxacin (Levaquin® Leva-pak), an antibiotic for patients with acute bacterial sinusitis and community-acquired pneumonia; valsartan (Diovan®), for left ventricular failure or left ventricular dysfunction; and dapsone gel (Aczone®), a topical therapy for acne vulgaris.
With advances in the treatment of MI, cardiologists are now focusing on improving the safety of drugs for heart disease. The author presents some new findings on aspirin, fondaparinux, enoxaparin, heparin, clopidogrel, and fish oil for prevention and treatment.